Photo of Joshua Brody from X
Aug 9, 2024, 10:21
Immunotherapy with chemo improves survival for aggressive relapsed lymphoma
Joshua Brody, Director of the Lymphoma Immunotherapy Program at the Icahn School of Medicine at Mount Sinai, shared on LinkedIn:
“In relapsed aggressive lymphoma, adding bispecific CD3xCD20 immunotherapy to chemo DOUBLES Overall Survival and Complete Remissions! To 59%!
STARGLO trial treating patients at ~70 hospitals around the world including Mount Sinai.”
Read further.
Source: Joshua Brody/LinkedIn